Vertex Pharmaceuticals (NASDAQ:VRTX) Given New $596.00 Price Target at Morgan Stanley

Vertex Pharmaceuticals (NASDAQ:VRTX) had its price target upped by Morgan Stanley from $570.00 to $596.00 in a report published on Tuesday,Benzinga reports. The brokerage currently has an overweight rating on the pharmaceutical company’s stock.

VRTX has been the subject of a number of other research reports. Barclays increased their target price on Vertex Pharmaceuticals from $606.00 to $607.00 and gave the stock an “overweight” rating in a report on Tuesday, February 17th. UBS Group raised their price target on shares of Vertex Pharmaceuticals from $535.00 to $545.00 and gave the stock a “buy” rating in a research note on Monday, January 26th. Weiss Ratings upgraded shares of Vertex Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, February 4th. Evercore boosted their price objective on shares of Vertex Pharmaceuticals from $475.00 to $530.00 and gave the stock an “outperform” rating in a research report on Friday, January 23rd. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $590.00 target price on shares of Vertex Pharmaceuticals in a research report on Friday, February 13th. Twenty-three investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat.com, Vertex Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $551.77.

Vertex Pharmaceuticals Price Performance

Shares of VRTX stock opened at $499.17 on Tuesday. Vertex Pharmaceuticals has a one year low of $362.50 and a one year high of $519.68. The stock has a market cap of $126.80 billion, a PE ratio of 32.56 and a beta of 0.31. The stock has a 50-day moving average of $468.41 and a 200-day moving average of $436.53.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its earnings results on Thursday, February 12th. The pharmaceutical company reported $5.03 earnings per share for the quarter, missing the consensus estimate of $5.05 by ($0.02). The firm had revenue of $3.19 billion during the quarter, compared to analyst estimates of $3.18 billion. Vertex Pharmaceuticals had a return on equity of 24.30% and a net margin of 32.94%.The company’s revenue for the quarter was up 9.5% on a year-over-year basis. During the same quarter last year, the business posted $3.98 earnings per share. As a group, research analysts anticipate that Vertex Pharmaceuticals will post 15.63 earnings per share for the current year.

Insider Activity

In other news, EVP Jonathan Biller sold 945 shares of the firm’s stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $486.35, for a total value of $459,600.75. Following the sale, the executive vice president directly owned 13,659 shares in the company, valued at approximately $6,643,054.65. This trade represents a 6.47% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Mark E. Bunnage sold 620 shares of the firm’s stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $486.35, for a total transaction of $301,537.00. Following the completion of the sale, the executive vice president owned 7,284 shares in the company, valued at $3,542,573.40. This represents a 7.84% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 91,156 shares of company stock worth $42,845,497. 0.20% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. PeakShares LLC bought a new stake in shares of Vertex Pharmaceuticals in the 4th quarter valued at $1,017,000. Corient Private Wealth LLC increased its position in Vertex Pharmaceuticals by 0.8% in the 4th quarter. Corient Private Wealth LLC now owns 102,570 shares of the pharmaceutical company’s stock valued at $46,510,000 after buying an additional 839 shares in the last quarter. Mengis Capital Management Inc. bought a new stake in shares of Vertex Pharmaceuticals during the fourth quarter valued at approximately $227,000. Rehmann Capital Advisory Group raised its holdings in Vertex Pharmaceuticals by 3.3% during the fourth quarter. Rehmann Capital Advisory Group now owns 1,937 shares of the pharmaceutical company’s stock worth $879,000 after buying an additional 61 shares during the last quarter. Finally, SHP Wealth Management bought a new position in Vertex Pharmaceuticals in the 4th quarter valued at about $220,000. 90.96% of the stock is owned by institutional investors.

Key Headlines Impacting Vertex Pharmaceuticals

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Vertex reported positive Week‑36 interim results from the Phase 3 RAINIER trial for povetacicept — the study met its primary and all secondary endpoints, supporting the drug’s potential as a best‑in‑class treatment for IgA nephropathy. Vertex Announces Positive Week 36 Interim Analysis Results
• Positive Sentiment: News outlets note the trial win as a major validation — coverage emphasizes the result as a “key test” passed and calls the data “remarkable,” boosting confidence in Vertex’s kidney‑disease strategy. Vertex passes key test In quest to treat kidney diseases
• Positive Sentiment: Interim efficacy metrics cited in coverage (e.g., ~52% reduction in proteinuria) raise hopes for meaningful clinical benefit and potential for an accelerated FDA filing pathway, increasing the drug’s peak‑sales and valuation assumptions. VRTX Stock Gains on Upbeat Interim Data From Kidney Disease Drug Study
• Positive Sentiment: Multiple brokerages responded quickly with higher price targets and fresh buy/outperform ratings (examples: Morgan Stanley, BofA, Oppenheimer, HC Wainwright, Citi, Jefferies, BMO and others), reflecting analysts modeling substantial upside from povetacicept. Benzinga — analyst price target coverage
• Neutral Sentiment: Vertex presented at the Leerink Global Healthcare Conference (transcript available), which may provide additional detail on timing, filing plans and commercial strategy but is less market‑moving than the trial headlines. Vertex Presents at Leerink Global Healthcare Conference 2026 Transcript
• Neutral Sentiment: Market commentary and aggregator pieces (Barron’s, Yahoo, Investopedia, TipRanks) are amplifying the newsflow — helpful for liquidity and momentum but reflecting the same core trial announcement rather than new independent data. Investopedia — trial results coverage

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.